Literature DB >> 30685706

Optical fiber amplifier for quantitative and sensitive point-of-care testing of myoglobin and miRNA-141.

Xiaofeng Liu1, Hua Zhang1, Shiya Qin1, Qing Wang2, Xiaohai Yang1, Kemin Wang3.   

Abstract

A simple, sensitive, quantitative point-of-care testing (POCT) was developed integrating enzyme-linked DNA supersandwich amplification with optical fiber amplifier. The point-of-care (POC) assay can work in both "Turn-off" mode and "Turn-on" mode. Using myoglobin (Myo) and miRNA-141 as the model biomarker, as low as 0.5 nM Myo and 10 pM miRNA-141 could be detected. More importantly, the optical fiber amplifier, which was used as signal readout, exhibited low-cost, small size, rapid response, and easy operation. Although it did not need large equipment and professional technical personnel, the assay was successfully applied to detect Myo and miRNA-141 in 40% human serum. Since the entire process of the strategy could be done directly in the centrifugal tube, requiring a few easy steps, it showed great potential application for early diagnosis in the world, especially in developing countries or remote regions. This work provided a new avenue for developing the portable and sensitive biosensor.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MiRNA-141; Myoglobin; Optical fiber amplifier; Point-of-care testing

Mesh:

Substances:

Year:  2019        PMID: 30685706     DOI: 10.1016/j.bios.2018.12.056

Source DB:  PubMed          Journal:  Biosens Bioelectron        ISSN: 0956-5663            Impact factor:   10.618


  2 in total

1.  An electrochemiluminescence immunosensor for myoglobin using an indium tin oxide glass electrode modified with gold nanoparticles and platinum nanowires.

Authors:  Bin Zou; Hongying Cheng; Yifeng Tu
Journal:  Mikrochim Acta       Date:  2019-08-02       Impact factor: 5.833

2.  Identification of miR‑25‑3p as a tumor biomarker: Regulation of cellular functions via TOB1 in breast cancer.

Authors:  Tianyi Zhao; Wenjing Meng; Yenlie Chin; Lili Gao; Xiyue Yang; Shuangyu Sun; Xingfang Pan; Lihong He
Journal:  Mol Med Rep       Date:  2021-03-31       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.